This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Stage I Multiple Myeloma Treatment (IFM-01-04)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2009 by Centre Hospitalier Universitaire de Nice.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice Identifier:
First received: August 12, 2008
Last updated: March 23, 2012
Last verified: February 2009
  • Assessment of survival without progression of stage I MM in two groups: arm A: simple survey and arm B: administration of Zoledronate.
  • Describe different progression's type noticed and define the prognosis factors of a fast evolution.

Condition Intervention Phase
Multiple Myeloma Drug: zometa Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Stage I Multiple Myeloma Treatment

Resource links provided by NLM:

Further study details as provided by Centre Hospitalier Universitaire de Nice:

Primary Outcome Measures:
  • Survival without progress [ Time Frame: every month during 6 years ]

Secondary Outcome Measures:
  • predictive factors of a fast evolution of multiple myeloma [ Time Frame: every month during 6 years ]
  • Secondary effects of zolédronate [ Time Frame: every month during six years ]

Estimated Enrollment: 350
Study Start Date: December 2004
Estimated Study Completion Date: November 2012
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
patients receiving zometa treatment
Drug: zometa
patients receiving treatment during their follow-up
No Intervention: 2
No treatment, just follow-up

Detailed Description:


Multiple Myeloma in spite of therapy progresses mainly due to stem cell auto transplant, still remain a deadly disease. About 2000 new cases are diagnosed every year in France. The asymptomatic Stage I MM according to Duries and Salmon's staging are usually only watch over and only treated at progression. Zoledronate is a third generation aminobiphosphonate (BP), probably the most powerful among the available compounds which received market clearance authorisation in MM with bone damage. During MM, bone's hyper resorption is premature. Interactions exist between tumor growth and bone lyses. Zoledronate's got a proper antimyeloma's action (induce plasma cells apoptosis). We propose to test the early use of Zoledronate as soon as stage I MM to delay progression.


  • PRINCIPAL: Assessment of survival without progression stage I MM in two groups: A arm: simple survey and B arm: administration of BP.
  • SECONDARY: Describe different progression's type noticed (bone/extra bone) and define the prognosis factor of a fast stage I MM evolution (standard factors, cytogenetic 13 deletion, bone's restructuring strains: crosslaps, bone alkaline phosphatase), list side effects.


Multicenter international randomised trial, open labelled, with individual profit.


Intergroupe Francophone du Myélome's centers.


Asymptomatic stage I MM without bone's lesion on the standard radiographs.


After checking inclusion and non inclusion specifications, the patient will be included in the study and randomized (A arm or B arm) before all treatment. The randomisation will be done by center and stratified according to the diagnostic date witch a year or not.

  • Arm A: simple survey as standard practice.
  • Arm B: a 15 minutes infusion of Zoledronate every month until progression or a maximum of 18 infusions if no progression. The exams are the one usually defined according to good clinical practices guidelines besides cytogenetic, bone's restructuring strain and serum creatin dosage before each infusion in B arm.


The minimum number of patients required showing a median survival time increase without progression of 26 months in the control arm and 38 months in the BP arm is about 175 patients in each arm for a 48 months inclusion's period, and a monitoring of 24 months after the last inclusion (i.e. a study's length of 6 years).


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • stage I multiple myeloma without bones injuries

Exclusion Criteria:

  • abnormal kidney function
  • VIH infection
  • Hepatic incapacity
  • pregnancy
  • Associate pathology
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00733538

Service de Medecine interne, Hôpital l'ARCHET, CHU de Nice
Nice, France, 06202
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Principal Investigator: Jean-Gabriel FUZIBET, PU-PH service de médecine interne, CHU de Nice
  More Information

Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT00733538     History of Changes
Other Study ID Numbers: IFM-04-01
Study First Received: August 12, 2008
Last Updated: March 23, 2012

Keywords provided by Centre Hospitalier Universitaire de Nice:
stage I multiple myeloma

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017